Replies to post #158599 on Biotech Values

[biomaven0]

Tefferi really is biased:

The results from COMFORT-1 (placebo-controlled) showed no
survival difference at an early time point but favored ruxolitinib
in the most recent analysis.

How about conceding that there was in fact a stat sig survival benefit with an HR under 0.6 and a p value less than .03?

INCY must not have picked up the tab for his dinner on some occasion. :)

Peter